Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 2_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... حسب Christopher L. Reading (21236861)

Data Sheet 1_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... حسب Christopher L. Reading (21236861)

Evolution of health burden and life expectancy under different expenditure scenarios. حسب Margherita Molaro (17803989)

الموضوعات:

Capabilities expansion scenarios considered. <i><i>g</i></i>_GDP and <i><i>g</i></i>_fHE refer to the growth rate of annual GDP (in constant 2015 US$) and growt... حسب Margherita Molaro (17803989)

الموضوعات:

Scaling of overall health burden with yearly expenditure growth. حسب Margherita Molaro (17803989)

الموضوعات:

Impact on different areas of health. حسب Margherita Molaro (17803989)

الموضوعات:

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

"…While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …"

Hemodynamic and respiratory changes over time. حسب Katharyn L. Flickinger (4759323)

Patient demographics. حسب Katrine Carlsen (5477300)

الموضوعات:

Alpha diversity measures across all 727 samples. حسب Katrine Carlsen (5477300)

الموضوعات:

STORMS microbiome reporting checklist. حسب Katrine Carlsen (5477300)

الموضوعات:

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Normalized significant family changes in abundance. حسب Karley K. Mahalak (3212670)

GLS inhibition decreases IL-1β secretion <i>in vitro</i>. حسب Bárbara Ponzilacqua-Silva (17002156)

EF-24 induces significant transcriptional changes in K-562 cells. حسب Ajeet P. Singh (22298432)

An infographic outlining the data used for each analysis. حسب Shelby L. Sturrock (10751675)

الموضوعات:

Summary map of all contacts with statistically significant SVM classifications. حسب Alexander P. Rockhill (6053618)

"…The middle row shows the directionality of spectral change for these significant SVM clusters during number trial conditions versus inter-trial intervals. …"